Information:
Error:
ID
23465
Description
Study of Enzastaurin Versus Placebo With Pemetrexed for Patients With Advanced or Metastatic Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00530621
Link
https://clinicaltrials.gov/show/NCT00530621
Keywords
Versions (1)
- 7/6/17 7/6/17 -
Uploaded on
July 6, 2017
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Non-small Cell Lung Cancer NCT00530621
Eligibility Non-small Cell Lung Cancer NCT00530621
- StudyEvent: Eligibility
Similar models
Eligibility Non-small Cell Lung Cancer NCT00530621
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
ID.1
Item
laboratory confirmed diagnosis of nsclc with locally advanced or metastatic disease which cannot be cured.
boolean
C0007131 (UMLS CUI [1,1])
C0278987 (UMLS CUI [1,2])
C0278987 (UMLS CUI [1,2])
ID.2
Item
patients must have disease which progressed after 1 prior systemic cytotoxic chemotherapy regimen for advanced disease.
boolean
C0278940 (UMLS CUI [1])
ID.3
Item
at least 1 measurable lesion.
boolean
C0221198 (UMLS CUI [1])
ID.4
Item
must have stopped all previous systemic therapies for cancer for at least 2 weeks prior to enrollment.
boolean
C0087111 (UMLS CUI [1,1])
C0444930 (UMLS CUI [1,2])
C0444930 (UMLS CUI [1,2])
ID.5
Item
must be able to follow study guidelines and be able to show up for appointments.
boolean
C1321605 (UMLS CUI [1])
ID.6
Item
treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
boolean
C0013230 (UMLS CUI [1])
ID.7
Item
previous treatment with enzastaurin or pemetrexed.
boolean
C1327830 (UMLS CUI [1,1])
C0210657 (UMLS CUI [1,2])
C0210657 (UMLS CUI [1,2])
ID.8
Item
concurrent administration of any other antitumor therapy.
boolean
C2986475 (UMLS CUI [1])
ID.9
Item
inability to swallow tablets
boolean
C0566357 (UMLS CUI [1,1])
C0039225 (UMLS CUI [1,2])
C0039225 (UMLS CUI [1,2])
ID.10
Item
pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0006147 (UMLS CUI [1,2])